Welcome

Pfizer Partners With Biovac to Boost Africa’s Vaccine Supply (2)

July 21, 2021, 5:30 PM

Pfizer Inc. said it reached an agreement to start production of its Covid-19 vaccine at a facility in Cape Town in an effort to deliver more than 100 million doses annually to African nations.

Pfizer and its German vaccine partner, BioNTech SE, said Wednesday they signed a letter of intent with Biovac Institute, a company partially owned by the South African government, to manufacture the shots. The companies expect to bring Biovac’s Cape Town-based facility into the fold of their broader coronavirus vaccine supply chain by the end of 2021, and to begin producing finished doses in 2022.

At ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.